| 刘承媛,魏素菊,马敏婷.促红细胞生成素治疗肿瘤相关性贫血的研究进展[J].肿瘤学杂志,2016,22(7):589-593. |
| 促红细胞生成素治疗肿瘤相关性贫血的研究进展 |
| Advances in Treatment of Cancer-related Anemia with Erythropoietin |
| 投稿时间：2016-01-04 |
| DOI：10.11735/j.issn.1671-170X.2016.07.B013 |
|
 |
| 中文关键词: 肿瘤相关性贫血 促红细胞生成素 生活质量 肿瘤转移 无病生存期 |
| 英文关键词:cancer-related anemia erythropoietin quality of life neoplasm metastasis disease-free survival |
| 基金项目: |
|
| 摘要点击次数: 2365 |
| 全文下载次数: 877 |
| 中文摘要: |
| 摘 要：贫血是恶性肿瘤常见的伴随疾病。肿瘤相关性贫血对患者存在较大的影响，可以降低患者生活质量、影响放化疗疗效等。促红细胞生成素（erythropoietin，EPO）是临床上治疗肿瘤相关性贫血的重要方式，其可提高患者血红蛋白水平、减少红细胞的输注、改善生活质量，但是使用EPO可以使血栓发生风险升高，关于是否影响患者总生存期、促进肿瘤转移等方面仍然存在争议。文章根据国内外相关文献，对EPO用于肿瘤相关性贫血患者的疗效及安全性进行总结。 |
| 英文摘要: |
| Abstract：Anemia is a common concomitant disease of malignant tumor. Cancer-related anemia would reduce the quality of life(QOL) and impact the efficacy of chemotherapy and radiotherapy. Erythropoietin(EPO) can increase hemoglobin level，reduce the frequency of red blood cell transfusion and improve the QOL of patients with cancer-related anemia. However，the use of EPO may increase the risk of thrombosis; and there is still a controversy about the possible impact of inducing tumor metastasis and affecting overall survival of patients after using EPO. Based on the literature，the efficacy and safety of EPO in treatment of cancer-related anemia are reviewed in this article. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |